Blood and Plasma Components Market.pdf

1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
res
Focus on Product, Application, End User
and Region
Analysis and Forecast: 2021-2031
April 2022
Blood and Plasma
Components
Market -
A Global and
Regional Analysis
Table of Content

2
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................26
1. Markets .....................................................................................33
1.1 Product Definition............................................................................................34
1.1.1 Inclusion and Exclusion Criteria................................................................34
1.2 Market Scope ...................................................................................................34
1.2.1 Scope of the Study......................................................................................34
1.2.2 Key Questions Answered in the Report ....................................................35
1.3 Research Methodology ...................................................................................36
1.3.1 Global Blood and Plasma Components Market: Research
Methodology ................................................................................................36
1.3.2 Data Sources ...............................................................................................37
1.3.2.1 Primary Data Sources........................................................................................ 37
1.3.2.2 Secondary Data Sources................................................................................... 38
1.3.3 Market Estimation Model ............................................................................39
1.3.4 Criteria for Company Profiling ...................................................................41
1.4 Market Overview ..............................................................................................41
1.4.1 Red Blood Cells...........................................................................................41
1.4.2 Platelets........................................................................................................42
1.4.3 Plasma..........................................................................................................42
1.4.4 Granulocytes ...............................................................................................42
1.5 Historical Trends in the Use of Blood Components .....................................43
1.6 Use of Blood Components..............................................................................45
1.7 Market Footprint and Future Potential, $Million, 2020-2031.........................46
2. Industry Analysis ......................................................................47
2.1 Overview...........................................................................................................48
2.2 Regulatory Framework....................................................................................48

4
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
2.2.1 Regulatory Framework in the U.S. .............................................................48
2.2.2 Regulatory Framework in the European Union.........................................50
2.2.3 Regulatory Framework in Asia-Pacific ......................................................51
2.2.3.1 China ................................................................................................................. 51
2.2.3.2 Japan................................................................................................................. 52
2.3 Supply Chain Analysis ....................................................................................53
2.4 Impact of COVID-19 on Global Blood and Plasma Components Market
...........................................................................................................................56
3. Market Dynamics ......................................................................58
3.1 Overview...........................................................................................................59
3.2 Impact Analysis ...............................................................................................59
3.3 Market Drivers..................................................................................................60
3.3.1 Global Increase in Patients with Blood Disorders....................................60
3.3.2 Increase in Trauma Patients and Chronic Illnesses.................................61
3.3.3 Rise in number of Product Launches and Approvals ..............................62
3.4 Market Restraints.............................................................................................63
3.4.1 Risk of Transfusion Transmitted Infectious Diseases and Adverse
Reaction Associated with Blood Transfusion...........................................63
3.4.2 Long Duration of Manufacturing Process and Strict Regulatory
Guidelines....................................................................................................65
3.5 Market Opportunities.......................................................................................67
3.5.1 Increase in Adoption of Business Expansion Strategies in the
Market...........................................................................................................67
4. Competitive Landscape .............................................................69
4.1 Overview...........................................................................................................70
4.2 Corporate Strategies .......................................................................................70
4.2.1 Mergers and Acquisitions...........................................................................70
4.2.2 Synergistic Activities ..................................................................................71

5
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
4.2.3 Business Expansion, Funding, and Reimbursement Activities ..............73
4.3 Business Strategies ........................................................................................74
4.3.1 Product Launches .......................................................................................74
4.3.2 Product Approvals ......................................................................................75
4.4 Market Share Analysis, by Company (2020)..................................................76
4.5 Growth-Share Analysis ...................................................................................78
5. Products, $Million, 2020-2031 ....................................................79
5.1 Overview...........................................................................................................80
5.2 Transfusion Market..........................................................................................81
5.2.1 Packed Red Blood Cells .............................................................................82
5.2.2 Platelet Products .........................................................................................83
5.2.3 Frozen Plasma .............................................................................................85
5.3 Plasma-Derived Products ...............................................................................86
5.3.1 Immunoglobulins.........................................................................................88
5.3.1.1 Intravenous Immunoglobulins............................................................................ 89
5.3.1.2 Subcutaneous Immunoglobulins........................................................................ 91
5.3.1.3 Other Immunoglobulins...................................................................................... 93
5.3.2 Coagulation Factor Concentrates..............................................................95
5.3.2.1 Coagulation Factor VIII Concentrate ................................................................. 97
5.3.2.2 Coagulation Factor IX Concentrate ................................................................... 98
5.3.2.3 von Willebrand Factor (vWF)........................................................................... 100
5.3.2.4 Prothrombin Complex Concentrates................................................................ 101
5.3.2.5 Coagulation Factor XIII Concentrate ............................................................... 102
5.3.3 Albumins....................................................................................................103
5.3.4 Proteinase Inhibitors.................................................................................104
5.3.5 Other Blood Derivatives............................................................................105
6. Application, $Million, 2020-2031...............................................106

6
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
6.1 Overview.........................................................................................................107
6.2 Hematology ....................................................................................................108
6.2.1 Hemoglobinopathy....................................................................................109
6.2.1.1 Thalassemia .................................................................................................... 110
6.2.1.2 Sickle Cell Disease.......................................................................................... 112
6.2.1.3 Platelet Refractoriness..................................................................................... 113
6.2.2 Hematologic Malignancies Management.................................................114
6.2.3 Coagulopathy ............................................................................................116
6.2.3.1 Hemophilia....................................................................................................... 117
6.2.3.2 von Willebrand Disease................................................................................... 119
6.2.3.3 Thrombosis...................................................................................................... 121
6.2.3.4 Thrombocytopenia........................................................................................... 123
6.3 Solid Tumor Management.............................................................................124
6.4 Others .............................................................................................................126
6.5 Emerging Areas of Application ....................................................................126
7. End Users, $Billion, 202020-2031.............................................128
7.1 Overview.........................................................................................................129
7.2 Hospitals and Specialty Clinics....................................................................130
7.3 Research Institutions ....................................................................................131
7.4 Diagnostic Laboratories................................................................................132
7.5 Other End Users ............................................................................................133
8. Region, $Million, 2020-2031 .....................................................135
8.1 Overview.........................................................................................................136
8.2 North America................................................................................................138
8.2.1 U.S. .............................................................................................................139
8.2.2 Canada .......................................................................................................140
8.3 Europe ............................................................................................................141

7
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
8.3.1 Germany.....................................................................................................142
8.3.2 U.K. .............................................................................................................143
8.3.3 France.........................................................................................................145
8.3.4 Italy .............................................................................................................146
8.3.5 Spain...........................................................................................................147
8.3.6 Rest-of-Europe...........................................................................................148
8.4 Asia-Pacific ....................................................................................................149
8.4.1 China ..........................................................................................................150
8.4.2 India............................................................................................................151
8.4.3 Japan..........................................................................................................152
8.4.4 Australia.....................................................................................................153
8.4.5 South Korea ...............................................................................................154
8.4.6 Singapore...................................................................................................154
8.4.7 Rest-of-Asia-Pacific...................................................................................155
8.5 Rest-of-the-World ..........................................................................................156
9. Market – Competitive Benchmarking & Company Profiles ........158
9.1 Overview.........................................................................................................159
9.2 CSL Limited....................................................................................................161
9.2.1 Company Overview ...................................................................................161
9.2.2 Role of CSL Limited in the Global Blood and Plasma Components
Market.........................................................................................................161
9.2.3 Key Competitors of the Company............................................................162
9.2.4 Financials...................................................................................................163
9.2.5 Key Insights About the Financial Health of the Company .....................165
9.2.6 Corporate Strategies.................................................................................165
9.2.6.1 Business Expansion ........................................................................................ 165
9.2.7 Business Strategies ..................................................................................165

8
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
9.2.7.1 Product Approval ............................................................................................. 165
9.2.8 SWOT Analysis..........................................................................................166
9.3 Grifols, S.A. ....................................................................................................167
9.3.2 Role of Grifols, S.A. in the Global Blood and Plasma Components
Market.........................................................................................................167
9.3.4 Financials...................................................................................................169
9.3.6.1 Mergers and Acquisitions ................................................................................ 171
9.3.6.2 Synergistic Activities........................................................................................ 171
9.3.6.3 Business Expansion and Funding ................................................................... 172
9.3.7.1 Product Launch................................................................................................ 172
9.3.8 SWOT Analysis..........................................................................................173
9.4 ADMA Biologics, Inc......................................................................................174
9.4.2 Role of ADMA Biologics, Inc. in the Global Blood and Plasma
Components Market..................................................................................174
9.4.4 Financials...................................................................................................176
9.4.7.1 Product Launches............................................................................................ 178
9.4.7.2 Product Approvals ........................................................................................... 178

9
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
9.4.8 SWOT Analysis..........................................................................................179
9.5 Takeda Pharmaceutical Company Limited..................................................180
9.5.2 Role of Takeda Pharmaceutical Company Limited in the Global
Blood and Plasma Components Market..................................................180
9.5.4 Financials...................................................................................................182
9.5.6 SWOT Analysis..........................................................................................184
9.6 GC Pharma .....................................................................................................185
9.6.2 Role of GC Pharma in the Global Blood and Plasma Components
Market.........................................................................................................185
9.6.4.2 Business Expansion ........................................................................................ 187
9.6.5 SWOT Analysis..........................................................................................187
9.7 Octapharma AG .............................................................................................188
9.7.2 Role of Octapharma AG in the Global Blood and Plasma
9.7.4 Financials...................................................................................................190
9.7.7 SWOT Analysis..........................................................................................192

10
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
9.8 Kedrion S.p.A.................................................................................................193
9.8.2 Role of Kedrion S.p.A in the Global Blood and Plasma Components
Market.........................................................................................................193
9.8.4 Financials...................................................................................................195
9.8.6.1 Mergers and Acquisitions ................................................................................ 196
9.8.8 SWOT Analysis..........................................................................................198
9.9 Emergent BioSolutions Inc...........................................................................199
9.9.2 Role of Emergent BioSolutions Inc. in the Global Blood and Plasma
9.9.4 Financials...................................................................................................201
9.9.6 SWOT Analysis..........................................................................................204
9.10 Bio Products Laboratory Ltd. .......................................................................205
9.10.2 Role of Bio Products Laboratory Ltd. in the Global Blood and
Plasma Components Market ....................................................................205

11
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
9.10.5.1 Product Launch................................................................................................ 207
9.10.6 SWOT Analysis..........................................................................................208
9.11 LFB S.A...........................................................................................................209
9.11.2 Role of LFB S.A. in Global Blood and Plasma Components Market.....209
9.11.5 SWOT Analysis..........................................................................................211
9.12 American red Cross.......................................................................................212
9.12.2 Role of American Red Cross in the Global Blood and Plasma
9.12.4 Financials...................................................................................................214
9.12.5 SWOT Analysis..........................................................................................215
9.13 Versiti, Inc.......................................................................................................216
9.13.2 Role of Versiti, Inc. in the Global Blood and Plasma Components
Market.........................................................................................................216
9.13.4 SWOT Analysis..........................................................................................217
9.14 Blood Centers of America.............................................................................218
9.14.2 Role of Blood Centers of America in the Global Blood and Plasma
9.14.3 Key Customers of the Company ..............................................................219

12
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
9.14.5 SWOT Analysis..........................................................................................220
9.15 Carter BloodCare...........................................................................................221
9.15.2 Role of Carter BloodCare in the Global Blood and Plasma
9.15.4 SWOT Analysis..........................................................................................222
9.16 Memorial Blood Centers ...............................................................................223
9.16.2 Role of Memorial Blood Centers in the Global Blood and Plasma
9.16.4 SWOT Analysis..........................................................................................225

13
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
List of Figures
Figure 1: Global Blood and Plasma Components Market, $Billion, 2020 and 2031
Figure 2: Impact Analysis of Market Drivers and Market Restraints on the Global Blood and Plasma
Components Market
Figure 3: Global Blood and Plasma Components Market Segmentation
Figure 4: Global Blood and Plasma Components Market (by Product), 2020 and 2031
Figure 5: Global Blood and Plasma Components Market (by Application), 2020 and 2031
Figure 6: Global Blood and Plasma Components Market (by End User), 2020 and 2031
Figure 7: Global Blood and Plasma Components Services Market Snapshot (by Region)
Figure 8: Global Blood and Plasma Components Market: Segmentation
Figure 9: Global Blood and Plasma Components Market: Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Global Blood and Plasma Components Market, $Billion, 2020-2031
Figure 14: Workflow of Biologics License Application (BLA) Process
Figure 15: China’s Regulatory Institutions under NMPA
Figure 16: Workflow of Drug Approval Process in Japan
Figure 17: Schematic Representation of Blood Supply Chain
Figure 18: Blood and Blood Components Storage Requirements
Figure 19: Global Blood and Plasma Components Market: COVID-19 Impact Analysis
Figure 20: Number of Patients with Bleeding Disorders, 2016-2020
Figure 21: Comparison of Manufacturing Process of Plasma-Derived Medicinal Products and Traditional
Pharmaceutical Products
Figure 22: Share of Key Developments, January 2018-January 2022
Figure 23: Share of Mergers and Acquisitions (by Company), January 2018-January 2022
Figure 24: Share of Synergistic Activities (by Company), January 2018-January2022
Figure 25: Share of Business Expansion, Funding, and Reimbursement Activities (by Company), January
2018-January 2022
Figure 26: Share of Product Launches (by Company), January 2018-January 2022
Figure 27: Share of Product Approvals (by Company), January 2018-January 2022

14
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Figure 28: Market Share Analysis of Global Blood and Plasma Components Market, by Company (2019
and 2020)
Figure 29: Growth-Share Analysis for Global Blood and Plasma Components Market (by Company), 2020
Figure 30: Global Blood and Plasma Components Market Segmentation (by Product)
Figure 31: Global Blood and Plasma Components Market (by Transfusion Market), $Billion, 2020-2031
Figure 32: Global Blood and Plasma Components Market (by Transfusion Market), 2020 and 2031
Figure 33: Global Blood and Plasma Components Market (Packed Red Blood Cells), $Billion, 2020-2031
Figure 34: Global Blood and Plasma Components Market (Platelet Products), $Billion, 2020-2031
Figure 35: Components of Plasma
Figure 36: Global Blood and Plasma Components Market (Frozen Plasma), $Billion, 2020-2031
Figure 37: Global Blood and Plasma Components Market (by Plasma-Derived Products, $Billion, 2020-
2031
Figure 38: Global Blood and Plasma Components Market (by Plasma-Derived Products), 2020 and 2031
Figure 39: Global Blood and Plasma Components Market (Immunoglobulins), $Billion, 2020-2031
Figure 40: Global Blood and Plasma Components Market (by Immunoglobulins), 2020 and 2031
Figure 41: Global Blood and Plasma Components Market (Intravenous Immunoglobulins), $Billion, 2020-
2031
Figure 42: Global Blood and Plasma Components Market (Subcutaneous Immunoglobulins), $Billion,
2020-2031
Figure 43: Global Blood and Plasma Components Market (Other Immunoglobulins), $Billion, 2020-2031
Figure 44: Coagulation Factor Concentrates Market Segmentation
Figure 45: Global Blood and Plasma Components Market (by Coagulation Factor Concentrates), $Billion,
2020-2031
Figure 46: Global Blood and Plasma Components Market (by Coagulation Factor Concentrates), 2020 and
2031
Figure 47: Global Blood and Plasma Components Market (Coagulation Factor VIII Concentrate), $Billion,
2020-2031
Figure 48: Global Blood and Plasma Components Market (Coagulation Factor IX Concentrate), $Billion,
2020-2031
Figure 49: Global Blood and Plasma Components Market (von Willebrand Factor), $Billion, 2020-2031
Figure 50: Global Blood and Plasma Components Market (Prothrombin Complex Concentrates), $Billion,
2020-2031
Figure 51: Global Blood and Plasma Components Market (Coagulation Factor XIII Concentrate), $Billion,
2020-2031
Figure 52: Global Blood and Plasma Components Market (Albumins), $Billion, 2020-2031

15
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Figure 53: Global Blood and Plasma Components Market (Proteinase Inhibitors), $Billion, 2020-2031
Figure 54: Global Blood and Plasma Components Market (Other Blood Derivatives), $Billion, 2020-2031
Figure 55: Global Blood and Plasma Components Market Segmentation (by Application)
Figure 56: Global Blood and Plasma Components Market (by Application), 2020 and 2031
Figure 57: Global Blood and Plasma Components Market (by Hematology), $Billion, 2020-2031
Figure 58: Global Blood and Plasma Components Market (by Hemoglobinopathy), $Billion, 2020-2031
Figure 59: Types of Thalassemia
Figure 60: Global Blood and Plasma Components Market (Thalassemia), $Billion, 2020-2031
Figure 61: Common Types of Sickle Cell Disease (SCD)
Figure 62: Global Blood and Plasma Components Market (Sickle Cell Disease), $Billion, 2020-2031
Figure 63: Global Blood and Plasma Components Market (Platelet Refractoriness), $Billion, 2020-2031
Figure 64: Global Blood and Plasma Components Market (Hematologic Malignancies Management),
$Billion, 2020-2031
Figure 65: Global Blood and Plasma Components Market (by Coagulopathy), $Billion, 2020-2031
Figure 66: Types of Hemophilia
Figure 67: Global Blood and Plasma Components Market (Hemophilia), $Billion, 2020-2031
Figure 68: Types of Von Willebrand’s Disease (vWD)
Figure 69: Global Blood and Plasma Components Market (von Willebrand Disease), $Billion, 2020-2031
Figure 70: Classification of Thrombosis
Figure 71: Global Blood and Plasma Components Market (Thrombosis), $Billion, 2020-2031
Figure 72: Different Causes of Thrombocytopenia
Figure 73: Global Blood and Plasma Components Market (Thrombocytopenia), $Billion, 2020-2031
Figure 74: Global Blood and Plasma Components Market (Solid Tumor Management), $Billion, 2020-2031
Figure 75: Global Blood and Plasma Components Market (Others), $Billion, 2020-2031
Figure 76: Global Blood and Plasma Components Market Segmentation (by End User)
Figure 77: Global Blood and Plasma Components Market (by End User), 2020 and 2031
Figure 78: Global Blood and Plasma Components Market (Hospitals and Specialty Clinics), $Billion, 2020-
2031
Figure 79: Global Blood and Plasma Components Market (Research Institutions), $Billion, 2020-2031
Figure 80: Global Blood and Plasma Components Market (Diagnostics Laboratories), $Billion, 2020-2031
Figure 81: Global Blood and Plasma Components Market (Other End Users), $Billion, 2021-2031
Figure 82: Global Blood and Plasma Components Services Market Snapshot (by Region)
Figure 83: Global Blood and Plasma Components Market (by Region), 2020 and 2031

16
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Figure 84: North America Blood and Plasma Components Market, $Billion, 2020-2031
Figure 85: U.S. Blood and Plasma Components Market, $Billion, 2020-2031
Figure 86: Canada Blood and Plasma Components Market, $Billion, 2020-2031
Figure 87: Europe Blood and Plasma Components Market, $Billion, 2020-2031
Figure 88: Germany Blood and Plasma Components Market, $Billion, 2020-2031
Figure 89: U.K. Blood and Plasma Components Market, $Billion, 2020-2031
Figure 90: France Blood and Plasma Components Market, $Billion, 2020-2031
Figure 91: Italy Blood and Plasma Components Market, $Billion, 2020-2031
Figure 92: Spain Blood and Plasma Components Market, $Billion, 2020-2031
Figure 93: Rest-of-Europe Blood and Plasma Components Market, $Billion, 2020-2031
Figure 94: Asia-Pacific Blood and Plasma Components Market, $Billion, 2020-2031
Figure 95: China Blood and Plasma Components Market, $Billion, 2020-2031
Figure 96: India Blood and Plasma Components Market, $Billion, 2020-2031
Figure 97: Japan Blood and Plasma Components Market, $Billion, 2020-2031
Figure 98: Australia Blood and Plasma Components Market, $Billion, 2020-2031
Figure 99: South Korea Blood and Plasma Components Market, $Billion, 2020-2031
Figure 100: Singapore Blood and Plasma Components Market, $Billion, 2020-2031
Figure 101: Rest-of-Asia-Pacific Blood and Plasma Components Market, $Billion, 2020-2031
Figure 102: Rest-of-the-World Blood and Plasma Components Market, $Billion, 2020-2031
Figure 103: Total Number of Companies Profiled
Figure 104: Global Blood and Plasma Components Market, Company Profile Overview
Figure 105: CSL Limited: Product Portfolio
Figure 106: CSL Limited: Overall Financials, $Million, 2018-2020
Figure 107: CSL Limited: Revenue (by Segment), $Million, 2018-2020
Figure 108: CSL Limited: Revenue (by Region), $Million, 2018-2020
Figure 109: CSL Limited: R&D Expenditure, $Million, 2018-2020
Figure 110: CSL Limited: SWOT Analysis
Figure 111: Grifols, S.A.: Product Portfolio
Figure 112: Grifols, S.A.: Overall Financials, $Million, 2018-2020
Figure 113: Grifols, S.A.: Revenue (by Segment), $Million, 2018-2020
Figure 114: Grifols, S.A.: Revenue (by Region), $Million, 2018-2020
Figure 115: Grifols, S.A.: R&D Expenditure, $Million, 2018-2020
Figure 116: Grifols, S.A.: SWOT Analysis

17
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Figure 117: ADMA Biologics, Inc.: Product Portfolio
Figure 118: ADMA Biologics, Inc.: Overall Financials, $Million, 2018-2020
Figure 119: ADMA Biologics, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 120: ADMA Biologics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 121: ADMA Biologics, Inc.: SWOT Analysis
Figure 122: Takeda Pharmaceutical Company Limited: Product Portfolio
Figure 123: Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020
Figure 124: Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020
Figure 125: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020
Figure 126: Takeda Pharmaceutical Company Limited: SWOT Analysis
Figure 127: GC Pharma: Product Portfolio
Figure 128: GC Pharma: SWOT Analysis
Figure 129: Octapharma AG: Product Portfolio
Figure 130: Octapharma AG: Overall Financials, $Million, 2018-2020
Figure 131: Octapharma AG: R&D Expenditure, $Million, 2018-2020
Figure 132: Octapharma AG: SWOT Analysis
Figure 133: Product Portfolio
Figure 134: Kedrion S.p.A: Overall Financials, $Million, 2018-2020
Figure 135: Kedrion S.p.A: Revenue (by Region), $Million, 2018-2020
Figure 136: Kedrion S.p.A: R&D Expenditure, $Million, 2018-2020
Figure 137: Kedrion S.p.A.: SWOT Analysis
Figure 138: Emergent BioSolutions Inc.: Product Portfolio
Figure 139: Emergent BioSolutions Inc.: Overall Financials, $Million, 2018-2020
Figure 140: Emergent BioSolutions Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 141: Emergent BioSolutions Inc.: Revenue (by Region), $Million, 2018-2020
Figure 142: Emergent BioSolutions Inc.: R&D Expenditure, $Million, 2018-2020
Figure 143: Emergent BioSolutions Inc.: SWOT Analysis
Figure 144: Bio Products Laboratory Ltd.: Product Portfolio
Figure 145: Bio Products Laboratory Ltd.: SWOT Analysis
Figure 146: LFB S.A.: Product Portfolio
Figure 147: LFB S.A.: SWOT Analysis
Figure 148: American Red Cross: Product Portfolio
Figure 149: American Red Cross: Overall Financials, $Million, 2018-2020

18
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Figure 150: American Red Cross: SWOT Analysis
Figure 151: Versiti, Inc.: Product Portfolio
Figure 152: Versiti, Inc.: SWOT Analysis
Figure 153: Blood Centers of America: Product Portfolio
Figure 154: Blood Centers of America: SWOT Analysis
Figure 155: Carter BloodCare: Product Portfolio
Figure 156: Carter BloodCare: SWOT Analysis
Figure 157: Memorial Blood Centers: Product Portfolio
Figure 158: Memorial Blood Centers: SWOT Analysis

19
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
List of Tables
Table 1: Differences between Neutrophils, Eosinophils, and Basophils
Table 2: Major Events in the Use of Blood and Plasma Components
Table 3: Likert Scale
Table 4: Impact Analysis of Market Drivers
Table 5: Impact Analysis of Market Restraints
Table 6: List of Acute Adverse Reactions and Delayed Adverse Reactions
Table 7: List of Companies Offering Intravenous Immunoglobulins (IVIGs)
Table 8: List of Companies Offering Subcutaneous Immunoglobulins (SCIGs)
Table 9: List of Companies Offering Intramuscular Immunoglobulins (IMIG)
Table 10: List of Companies Offering Coagulation Factor VIII Concentrate
Table 11: List of Companies Offering Coagulation Factor IX Concentrate
Table 12: List of Companies Offering von Willebrand Factor
Table 13: List of Key Competitors of CSL Limited
Table 14: List of Key Competitors of Grifols, S.A.
Table 15: List of Key Competitors of ADMA Biologics, Inc.
Table 16: List of Key Competitors of Takeda Pharmaceutical Company Limited
Table 17: List of Key Competitors of GC Pharma
Table 18: List of Key Competitors of Octapharma AG
Table 19: List of Key Competitors of Kedrion S.p.A
Table 20: List of Key Competitors of Emergent BioSolutions Inc.
Table 21: List of Key Competitors of Bio Products Laboratory Ltd.
Table 22: List of Key Competitors of LFB S.A.
Table 23: List of Key Competitors of American Red Cross
Table 24: List of Key Competitors of Versiti, Inc.
Table 25: List of Key Customers of Blood Centers of America
Table 26: List of Key Competitors of Blood Centers of America
Table 27: List of Key Competitors of Carter BloodCare
Table 28: List of Key Competitors of Memorial Blood Centers

20
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

21
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published, or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates, and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties, and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

22
G
L
O
B
A
L
B
L
O
O
D
A
N
D
P
L
A
S
M
A
C
O
M
P
O
N
E
N
T
S
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Blood and Plasma Components Market.pdf

Recommended

Recommended

More Related Content

Similar to Blood and Plasma Components Market.pdf

Similar to Blood and Plasma Components Market.pdf (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Blood and Plasma Components Market.pdf